Neuland Laboratories Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Neuland Laboratories Ltd filed with BSE on 10 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Neuland Laboratories reported total income of INR650.1 crores for Q1FY27, up 16.3% year-on-year, with EBITDA margin at 35.5% and PAT of INR147.4 crores compared to INR13.7 crores a year earlier. Management attributed growth primarily to commercial CMS projects and a favorable customer mix, while working capital days improved from 137 to 84. The company also discussed a strategic collaboration with Gland Pharma for sterile API manufacturing and progress on its peptide manufacturing facility, which is expected to be commissioned the following month.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Total income: INR650.1 crores (Q1FY27)
p. 3
“The total income for the quarter was INR650.1 crores as compared to INR300.6 crores in the corresponding quarter of the previous year, representing a growth of 16.3%.”
Abhijit Majumdar, page 3 of the filed PDF · View the filing
EBITDA margin: 35.5% (Q1FY27)
p. 3
“EBITDA for the quarter stood at INR231.1 crores with an EBITDA margin of 35.5%.”
Abhijit Majumdar, page 3 of the filed PDF · View the filing
Gross margin: 61.2% (Q1FY27)
p. 3
“The gross margin for the quarter was 61.2% as compared to 55.3% in Q1FY26, again, a function of our business mix during the quarter.”
Abhijit Majumdar, page 3 of the filed PDF · View the filing
Profit after tax: INR147.4 crores (Q1FY27)
p. 3
“Profit after tax for the quarter stood at INR147.4 crores as compared to INR13.7 crores in Q1FY26.”
Abhijit Majumdar, page 3 of the filed PDF · View the filing
Earnings per share: INR114.9 per share (Q1FY27)
p. 3
“Earnings per share for the quarter stood at INR114.9 per share.”
Abhijit Majumdar, page 3 of the filed PDF · View the filing
Working capital days: 84 days (Q1FY27)
p. 3
“Working capital days improved from 137 days at the end of FY26 to 84 days in FY27.”
Abhijit Majumdar, page 3 of the filed PDF · View the filing
Capital expenditure cash outflow: INR121.6 crores (Q1FY27)
p. 4
“there was a cash outflow of INR121.6 crores towards capital expenditure during Q1FY27, which was primarily driven by new R&D and peptide facilities.”
Abhijit Majumdar, page 4 of the filed PDF · View the filing
Approved capital investments: INR203 crores (Q1FY27)
p. 4
“During the quarter, we also approved capital investments of approximately INR203 crores, of which INR196 crores is earmarked for strategic growth initiatives, largely related to capacity expansion at our Unit 1.”
Abhijit Majumdar, page 4 of the filed PDF · View the filing
Total approved capex: INR1,460 crores (last 13 quarters)
p. 4
“Against total approved capex of INR1,460 crores over the last 13 quarters, we have spent INR870 crores to date, with the balance committed towards projects under implementation.”
Abhijit Majumdar, page 4 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — about 20% · FY27 and FY28
stated as an aspiration by Saharsh Davuluri
p. 7
“I think we've always aspired to grow at about 20%, and we expect that FY27& FY28 also we expect to grow that way.”
Saharsh Davuluri, page 7 of the filed PDF · View the filing
EBITDA margin — 25% plus · long term
stated as an aspiration by Saharsh Davuluri
p. 14
“But I think in terms of our plans, in terms of our long term, 25% plus is what we would be coming for.”
Saharsh Davuluri, page 14 of the filed PDF · View the filing
Peptide facility commissioning — commissioned next month · next month
stated firmly by Saharsh Davuluri
p. 8
“So the plant itself is going to be commissioned next month, and then it will be ready for manufacturing qualification will be done by then.”
Saharsh Davuluri, page 8 of the filed PDF · View the filing
New commercial molecule — one more commercialization this year, 1 or 2 next year · FY27 and next year
stated as an aspiration by Saharsh Davuluri
p. 9
“As I had mentioned in the past, we expect to have one more commercialization this year, probably have 1 or maybe even 2 next year.”
Saharsh Davuluri, page 9 of the filed PDF · View the filing
ROCE — expansion period
stated conditionally by Saharsh Davuluri
p. 16
“But if we are going to go into an expansion mode and we will have to deploy more capital for long term, we should have the ability to absorb a longer gestation period, which would mean lower ROCE for a shorter period.”
Saharsh Davuluri, page 16 of the filed PDF · View the filing
Development revenue — this year, with commercial contribution from FY28 onwards
stated as an aspiration by Saharsh Davuluri
p. 15
“No, I think this year, we'll see development revenue go up, and we have talked about it.”
Saharsh Davuluri, page 15 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said it aspires to ~20% growth but declined to give a specific FY27 number, and said destocking risk is already factored into order visibility.
Answered by Saharsh Davuluri
Asked by Amey Chalke: What growth should be expected for FY27 and is there risk from destocking of commercial contracts?
p. 7
“Not really, Amey. I think because the order visibility is consistent with the commentary, I would say destocking or stocking is factored into that.”
Saharsh Davuluri, page 7 of the filed PDF · View the filing
Management said two new advanced-clinic projects have come in, some of them peptide projects, but declined to quantify revenue this year.
Answered by Saharsh Davuluri
Asked by Shyam Srinivasan: How will development revenues pan out in FY27 given the pipeline?
p. 8
“It may not be very helpful or it may be premature to kind of quantify that revenue for this year.”
Saharsh Davuluri, page 8 of the filed PDF · View the filing
Management confirmed growth is driven by a handful of molecules (about three) rather than being broadly diversified, though more projects are being added.
Answered by Saharsh Davuluri
Asked by Sajal Kapoor: Is commercial CMS growth diversified across molecules and customers or driven by a few large programs?
p. 8
“There's not too many of them, I would say, maybe about 3 of them that really drive our business.”
Saharsh Davuluri, page 8 of the filed PDF · View the filing
Management said Q4 was an inflated quarter due to Q3 spillover and cautioned against using it as a base, reiterating that FY27 and FY28 should be good years.
Answered by Saharsh Davuluri
Asked by Chirag Shah: Was the Q4-to-Q1 sequential decline due to customer destocking, and is Q1 a normalized run rate?
p. 12
“I will rehyphenate Q4 because Q4 is exceptionally big.”
Saharsh Davuluri, page 12 of the filed PDF · View the filing
Management said development revenue is product-specific and tied to launch quantities, not a change in selection strategy, and said the pipeline quality continues to improve.
Answered by Saharsh Davuluri
Asked by Chirag Shah: Has the approach to selecting development products changed, leading to structurally lower development revenue?
p. 13
“I can assure you that our quality of development pipeline is only getting better and better.”
Saharsh Davuluri, page 13 of the filed PDF · View the filing
Management explained the collaboration leverages Gland's sterile manufacturing strength and Neuland's complex API capability, is asset-light, and covers niche generic category products.
Answered by Saharsh Davuluri
Asked by Kushal Chovatia: Why did Neuland partner with Gland Pharma and for what products?
p. 14
“These are all like niche category.”
Saharsh Davuluri, page 14 of the filed PDF · View the filing
Management said the margin profile is reasonable and healthy but ROCE may dip during an expansion phase due to higher capital deployment.
Answered by Saharsh Davuluri
Asked by Gulab Soni: Is the current margin profile at its peak or is there more scope for operating leverage?
p. 16
“ROCE is something that maybe is going to kind of ebb and flow because right now, our 3-year ROCE is quite healthy.”
Saharsh Davuluri, page 16 of the filed PDF · View the filing
Management confirmed a couple of projects are ready to use the new peptide facility and said an FDA inspection is expected but is not seen as a gating issue since the site is already FDA-approved.
Answered by Saharsh Davuluri
Asked by Tirumala Reddy: Does the peptide manufacturing plant have order book visibility, and does it need FDA inspection before commercial operation?
p. 16
“we don't necessarily see that as a gating issue because the plant itself that it is located in one is an FDA-approved site.”
Saharsh Davuluri, page 16 of the filed PDF · View the filing
Risks flagged
Business remains inherently uneven and lumpy on a quarterly basis
p. 3
“I'd like to reiterate our long-standing view regarding the inherent uneven nature of our business and the need to assess performance over a longer period rather than to a single quarter.”
Abhijit Majumdar, page 3 of the filed PDF · View the filing
Geopolitical and macroeconomic developments could affect operations and supply chain
p. 4
“During the quarter, we continue to closely monitor the evolving geopolitical environment and broader global trade development.”
Abhijit Majumdar, page 4 of the filed PDF · View the filing
Commercial revenue concentration in a handful of molecules creates volatility
p. 12
“But at the same time, our commercial revenues are driven by a handful of molecules. So they are subject to volatility and that volatility will be there.”
Saharsh Davuluri, page 12 of the filed PDF · View the filing
New peptide facility building is subject to future FDA audit
p. 16
“However, given that it is a new building, it's subject to FDA audit, but that is really dependent on how the FDA would look at the filing when it's made.”
Saharsh Davuluri, page 16 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.